New maternal vaccines could reduce infant deaths at and after birth, especially in low- and middle-income countries. Work is underway to prepare for new maternal vaccines globally, and the Maternal ...
Community engagement is a critical component of clinical trials, fostering dynamic and collaborative relationships between researchers, policymakers, and communities. It is not only an ethical requirement mandated by most ethics’ ...
From 2 – 5 March 2025, The Global Health Network participated in the Africa Health Agenda International Conference (AHAIC) in Kigali, Rwanda, joining policymakers, researchers, and health leaders to ...
Brain Infections Global have successfully developed and implemented an intervention that improved the diagnosis and management of brain infections such as meningitis in hospitals across Brazil, India and Malawi. Acute ...
Are you a nurse or midwife who has led a research study in a Low-and Middle-Income Country? The Global Health Network wants to hear from you. About the Study ...
SPEAC announces the release of a comprehensive Companion Guide for the Brighton Collaboration Case Definition of Single Organ Cutaneous Vasculitis (SOCV). This new resource combines a wealth of tools and guidance to standardize vaccine safety assessments and pharmacovigilance efforts worldwide. Read more
CEPI and ANVISA hosted this workshop to update global regulators on the marketing authorisation and clinical development plans in preparation for phase IV studies and future global approvals. There was robust dialogue and participation from 18 countries representing 14 NRAs. Read more
In June 2024, CEPI convened a workshop in Nairobi, Kenya, to discuss epidemiology and modeling for human RVF vaccine development, bringing together representatives from RVF-endemic countries, global collaborators, and international health organizations. This paper summarizes the workshop discussions and priorities. Read more
The African Union has set an ambitious goal: by 2040 over 60% of the vaccines needed for Africa’s population should be produced locally. A sustainable supply chain for the specialized input materials that go into making vaccines will be required Read more
This effort was funded by the National Institutes of Health, National Institutes of Allergy and Infectious Diseases, and CEPI. Data generated from using the Standard will help to inform current vaccine development and deployment strategies. Read more
The objective of the RPP is to leverage investments for advanced-stage clinical development of CEPI's portfolio vaccines and support countries in key regions to generate emergency evidence in future outbreaks Read more
Resources
In collaboration with TGHN, CEPI created this playbook to bring together the many tools, resources and materials generated for pandemic preparedness and response from the COVID-19 pandemic. The first (Regulatory) chapter is now available.
TRANSVAC Academy offers training modules in vaccine R&D including grant management, statistics, cytometry and advanced process development. CEPI funded scholarships are provided to selected applicants from LMICs.
SPEAC is a CEPI and Brighton Collaboration project. SPEAC provides vaccine safety tools, resources, and expertise throughout the vaccine development process to enhance safety and build confidence in vaccines.
Monitoring Vaccine Performance against SARS CoV-2 Variants
The IVAC COVID-19 Vaccine Effectiveness Project (a CEPI- funded global systematic review which also includes neutralization capacity) outputs are publicly available on VIEWhub to assist all policy makers
International Pandemic Preparedness Secretariat
The IPPS serves to join up relevant states, the private sector, and global health institutions in support of the 100 Days Mission, across vaccines, therapeutics, and diagnostics. It performs a global annual progress review related to the 100 DM which feeds into implementation reports.
Vaccine Development
Process Maps
The UK Vaccine R&D Network has developed vaccine development maps to show key stages in human and veterinary vaccines development up to Phase III clinical trials. These process maps and associated case studies provide support in understanding key stages in vaccine development and where bottlenecks could cause delays.
